FrancophonIA/ELRC3.0 huggingface dataset:
English: If serum phosphate is < 1.5 mg/dL (0.48 mmol/L) or creatinine clearance is decreased to < 60 mL/min in any individual receiving Emtricitabine/Tenofovir disoproxil Krka for pre-exposure prophylaxis, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Latvian: Ja fosfātu līmenis serumā ir < 1,5 mg/dl (0,48 mmol/l) vai kreatinīna klīrenss ir pazeminājies līdz < 60 ml/min visiem indivīdiem, kas saņem Emtricitabine/Tenofovir disoproxil Krka pirmskontakta profilaksei, nieru darbība atkārtoti jāpārbauda pēc vienas nedēļas, tostarp jānosaka glikozes koncentrācija asinīs, kālija koncentrācija asinīs un glikozes koncentrācija urīnā (skatīt 4.8. apakšpunktu, proksimāla tubulopātija).
English: HIV-1 RNA < 400 copies/mL (TLOVR)
Latvian: HIV-1 RNS < 400 kopijas/ml (TLOVR) p vērtība % atšķirība (95% TI)
English: Tenofovir disoproxil 245 mg
Latvian: 245 mg tenofovīra disoproksila
English: AUC: ↓ 5% (↓ 9 to ↓ 1) Cmax: ↓ 11% (↓ 17 to ↓ 5) Cmin: NC
Latvian: AUC: ↓ 5% (↓ 9 to ↓ 1) Cmax: ↓ 11% (↓ 17 to ↓ 5) Cmin: NA
English: If serum phosphate is < 1.5 mg/dL (0.48 mmol/L) or creatinine clearance is decreased to < 50 mL/min in any patient receiving Emtricitabine/Tenofovir disoproxil Krka, renal function should be reevaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Latvian: Ja fosfātu līmenis serumā ir < 1,5 mg/dl (0,48 mmol/l) vai kreatinīna klīrenss ir pazeminājies līdz < 50 ml/min, visiem pacientiem, kas saņem Emtricitabine/Tenofovir disoproxil Krka, nieru darbība atkārtoti jāpārbauda pēc vienas nedēļas, tostarp jānosaka glikozes koncentrācija asinīs, kālija koncentrācija asinīs un glikozes koncentrācija urīnā (skatīt 4.8. apakšpunktu, proksimāla tubulopātija).
English: If serum phosphate is confirmed to be < 3.0 mg/dl (0.96 mmol/l) in any paediatric patient receiving Emtricitabine/Tenofovir disoproxil Krka, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Latvian: Ja apstiprinātais fosfātu līmenis serumā ir < 3,0 mg/dl (0,96 mmol/l) jebkuram pediatriskajam pacientam, kas saņem Emtricitabine/Tenofovir disoproxil Krka, nieru darbība atkārtoti jāpārbauda pēc vienas nedēļas, tostarp jānosaka glikozes koncentrācija asinīs, kālija koncentrācija asinīs un glikozes koncentrācija urīnā (skatīt 4.8. apakšpunktu, proksimāla tubulopātija).
English: Moderate renal impairment (CrCl 3049 mL/min)
Latvian: Vidēji smagi nieru darbības traucējumi (kreatinīna klīrenss 30-49 ml/min)
English: ORAL CONTRACEPTIVES Norgestimate/Ethinyl oestradiol/Tenofovir disoproxil
Latvian: KONTRACEPCIJAS LĪDZEKĻI Norgestimāts/etinilestradiols/ tenofovīra disoproksils
English: AUC: ↓ 25% (↓ 42 to ↓ 3) Cmax: ↓ 28% (↓ 50 to ↑ 5) Cmin: ↓ 26% (↓ 46 to ↑ 10) Tenofovir:
Latvian: AUC: ↓ 25% (↓ 42 līdz ↓ 3) Cmax: ↓ 28% (↓ 50 līdz ↑ 5) Cmin: ↓ 26% (↓ 46 līdz ↑ 10)
English: Consideration should be given to interrupting use of Emtricitabine/Tenofovir disoproxil Krka in individuals with creatinine clearance decreased to < 60 mL/min or decreases in serum phosphate to < 1.0 mg/dL (0.32 mmol/L).
Latvian: Indivīdiem, kuriem kreatinīna klīrenss pazeminājies līdz < 60 ml/min vai fosfātu līmenis serumā pazeminājies līdz < 1,0 mg/dl (0,32 mmol/l), ir jāapsver Emtricitabine/Tenofovir disoproxil Krka lietošanas pārtraukšanas iespēja.
English: interleukin-2 (to treat cancer) cidofovir (for viral infection) non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)
Latvian: - aminoglikozīdi (bakteriālas infekcijas ārstēšanai); - amfotericīns B (sēnīšinfekcijas ārstēšanai); - foskarnets (vīrusinfekcijas ārstēšanai); - ganciklovīrs (vīrusinfekcijas ārstēšanai); - pentamidīns (infekciju ārstēšanai); - vankomicīns (bakteriālas infekcijas ārstēšanai); - interleikīns-2 (vēža ārstēšanai); - cidofovīrs (vīrusinfekcijas ārstēšanai); - nesteroīdie pretiekaisuma līdzekļi (NPL, lai atvieglotu kaulu vai muskuļu sāpes).
English: AUC: ↓ 7% (↓ 13 to ↓ 1) Cmax: ↓ 11% (↓ 20 to ↑ 1) Cmin: NC
Latvian: AUC: ↓ 7% (↓ 13 to ↓ 1) Cmax: ↓ 11% (↓ 20 to ↑ 1) Cmin: NA
English: AUC: ↓ 2% (↓ 5 to ↑ 0) Cmax: ↓ 1% (↓ 7 to ↑ 6) Cmin: NC
Latvian: AUC: ↓ 2% (↓ 5 to ↑ 0) Cmax: ↓ 1% (↓ 7 to ↑ 6) Cmin: NA
English: It is preferable that Emtricitabine/Tenofovir disoproxil Krka is taken with food.
Latvian: Ieteicams Emtricitabine/Tenofovir disoproxil Krka lietot kopā ar ēdienu.
English: Just taking Emtricitabine/Tenofovir disoproxil Krka may not stop you getting HIV.
Latvian: - Emtricitabine/Tenofovir disoproxil Krka lietošana pati par sevi nevar novērst HIV iegūšanu.
English: If vomiting occurs within 1 hour of taking Emtricitabine/Tenofovir disoproxil Krka, another tablet should be taken.
Latvian: Ja 1 stundas laikā pēc Emtricitabine/Tenofovir disoproxil Krka lietošanas sākas vemšana, jālieto otra tablete.
English: If renal abnormalities are detected or suspected then consultation with a nephrologist should be obtained to consider interruption of Emtricitabine/Tenofovir disoproxil Krka treatment - That Emtricitabine/Tenofovir disoproxil Krka may cause a reduction in BMD and the effects of Emtricitabine/Tenofovir disoproxil Krka associated changes in BMD on long term bone health and future fracture risk are currently unknown in paediatric patients - That if bone abnormalities are detected or suspected then consultation with an endocrinologist and/or nephrologist should be obtained
Latvian: - Emtricitabine/Tenofovir disoproxil Krka var izraisīt KMB samazināšanos, un šobrīd nav zināms, kāda ir ar Emtricitabine/Tenofovir disoproxil Krka lietošanu saistīto KMB izmaiņu ilgtermiņa ietekme uz kaulu veselību un lūzumu risku nākotnē pediatriskajiem pacientiem.
English: Separate preparations of emtricitabine and tenofovir disoproxil are available for treatment of HIV-1 infection if it becomes necessary to discontinue or modify the dose of one of the components of
Latvian: Ja terapija ar kādu no Emtricitabine/Tenofovir disoproxil Krka sastāvdaļām jāpārtrauc vai nepieciešama devas pielāgošana, ir pieejami atsevišķi emtricitabīna un tenofovīra disoproksila preparāti HIV-1 infekcijas ārstēšanai.
English: AUC: ↓ 27% (↓ 35 to ↓ 18) Cmax: ↓ 37% (↓ 48 to ↓ 25) GS-331007
Latvian: AUC: ↓ 27% (↓ 35 līdz ↓ 18) Cmax: ↓ 37% (↓ 48 līdz ↓ 25)
English: At baseline the randomised groups had similar median plasma HIV-1 RNA (5.02 and 5.00 log10 copies/mL) and CD4 counts (233 and 241 cells/mm
Latvian: Sākuma stāvoklī, pēc nejaušības principa atlasītām grupām bija līdzīgs mediānais plazmas HIV-1 RNS (5,02 un 5,00 log10 kopijas/ml) un CD4 šūnu skaits (233 un 241 šūnas/mm Pētījuma primārais efektivitātes mērķa kritērijs bija iegūt un uzturēt pierādītu HIV-1 RNS koncentrāciju < 400 kopijās/ml 48 nedēļu periodā.
English: AUC: ↑ 96% (↑ 74 to ↑ 121) Cmax: ↑ 68% (↑ 54 to ↑ 84) Cmin: ↑ 118% (↑ 91 to ↑ 150) Sofosbuvir:
Latvian: AUC: ↑ 96% (↑ 74 līdz ↑ 121) Cmax: ↑ 68% (↑ 54 līdz ↑ 84) Cmin: ↑ 118% (↑ 91 līdz ↑ 150)
English: Only samples from subjects randomized to emtricitabine/tenofovir disoproxil were evaluated for detectable plasma or intracellular tenofovir disoproxil-DP levels.
Latvian: Atklājamie tenofovīra disoproksila-DF līmeņi plazmā un intracelulārajā telpā tika novērtēti tikai paraugos, kas paņemti no emtricitabīna/tenofovīra disoproksila lietošanai randomizētajām personām.
English: Therefore Emtricitabine/Tenofovir disoproxil Krka should not be used during breast-feeding.
Latvian: Tāpēc Emtricitabine/Tenofovir disoproxil Krka nav ieteicams lietot bērna barošanas ar krūti laikā.
English: Tests may also show: low white blood cell count (a reduced white blood cell count can make you more prone to infection) increased triglycerides (fatty acids), bile or sugar in the blood liver and pancreas problems
Latvian: - mazu balto asins šūnu skaitu (samazināts balto asins šūnu skaits var padarīt Jūs jūtīgāku pret infekciju);
English: If you are being treated for HIV infection your doctor will prescribe Emtricitabine/Tenofovir disoproxil Krka with other antiretroviral medicines.
Latvian: - Ja Jūs saņemat HIV infekcijas ārstēšanu ārsts parakstīs Emtricitabine/Tenofovir disoproxil
English: Emtricitabine/Tenofovir disoproxil Krka can cause dizziness.
Latvian: Emtricitabine/Tenofovir disoproxil Krka var izraisīt reiboni.
English: Uncommon side effects (may affect up to 1 in 100 people) pain in the abdomen (tummy) caused by inflammation of the pancreas swelling of the face, lips, tongue or throat anaemia (low red blood cell count) breakdown of muscle, muscle pain or weakness which may occur due to damage to the kidney tubule cells
Latvian: - sāpes vēderā, ko izraisa aizkuņģa dziedzera iekaisums; - sejas, lūpu, mēles vai rīkles pietūkums; - anēmija (mazs sarkano asins šūnu skaits); - muskuļu sabrukums, muskuļu sāpes, muskuļu vājums, kas var rasties nieru kanāliņu šūnu bojājuma dēļ.
English: Emtricitabine/Tenofovir disoproxil Krka may affect your kidneys.
Latvian: - Emtricitabine/Tenofovir disoproxil Krka var ietekmēt nieru darbību.
English: HIV-1 uninfected individuals should be counselled at frequent intervals to strictly adhere to the recommended Emtricitabine/Tenofovir disoproxil Krka dosing schedule.
Latvian: Ar HIV-1 neinficētiem indivīdiem ir bieži jādod norādījumi stingri ievērot ieteikto
English: Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg film-coated tablets
Latvian: Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg apvalkotās tabletes
English: AUC: ↓ 9% (↓ 16 to ↓ 1) Cmax: ↓ 7% (↓ 22 to ↑ 11) Cmin: NC
Latvian: AUC: ↓ 9% (↓ 16 to ↓ 1) Cmax: ↓ 7% (↓ 22 to ↑ 11) Cmin: NA
English: HIV-Positive Subjects HIV-Negative Matched Control Subjects 63 (44%)
Latvian: HIV pozitīvas personas Atbilstoši HIV negatīvas kontroles personas
English: Mean change from baseline in CD4 cell count (cells/mm p-value
Latvian: CD4 šūnu skaita vidējās pārmaiņas, salīdzinot ar sākotnējo stāvokli (šūnas/mm p vērtība Atšķirība (95% TI)
English: How to store Emtricitabine/Tenofovir disoproxil Krka
Latvian: Kā uzglabāt Emtricitabine/Tenofovir disoproxil Krka
English: FTC/tenofovir disoproxil Group
Latvian: FTC/tenofovīra disoproksila grupa Tenofovīra disoproksila grupa
English: The risk of HIV-1 infection should be balanced against the potential for renal and bone effects with long-term use of emtricitabine/tenofovir.
Latvian: Ilgstoši lietojot emtricitabīnu/tenofovīru, ir jāizvērtē HIV-1 infekijas riska attiecība pret iespējamo iedarbību uz nierēm un kauliem.
English: IMMUNOSUPPRESSANTS Tacrolimus/Tenofovir disoproxil /Emtricitabine
Latvian: IMŪNSUPRESANTI Takrolims/tenofovīra disoproksils /emtricitabīns
English: Emtricitabine+ tenofovir disoproxil +efavirenz
Latvian: Emtricitabīns+ tenofovīra disoproksils+efavirenzs
English: Consideration should be given to interrupting treatment with Emtricitabine/Tenofovir disoproxil Krka in patients with creatinine clearance decreased to < 50 mL/min or decreases in serum phosphate to < 1.0 mg/dL (0.32 mmol/L).
Latvian: Pacientiem, kuriem kreatinīna klīrenss pazeminājies līdz < 50 ml/min vai fosfātu līmenis serumā pazeminājies līdz < 1,0 mg/dl (0,32 mmol/l), ir jāapsver arī Emtricitabine/Tenofovir disoproxil Krka terapijas pārtraukšanas iespēja.
English: Before taking Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV:
Latvian: Pirms Emtricitabine/Tenofovir disoproxil Krka lietošanas, lai samazinātu HIV iegūšanas risku:
English: vesiculobullous rash, pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discolouration (increased pigmentation)
Latvian: vezikulobullozi izsitumi, pustulozi izsitumi, makulopapulozi izsitumi, izsitumi, nieze, nātrene, ādas krāsas pārmaiņas (pastiprināta pigmentācija)
English: Do not stop taking Emtricitabine/Tenofovir disoproxil Krka
Latvian: Nepārtrauciet lietot Emtricitabine/Tenofovir disoproxil Krka
English: - HIV renal educational brochure - HIV pediatric renal educational brochure - PrEP educational brochure for prescribers entitled ‘Important Safety Information for
Latvian: - Informatīvā brošūra par pirmskontakta profilaksi zāļu parakstītājiem “Svarīga drošuma informācija zāļu parakstītājiem par Emtricitabine/Tenofovir disoproxil Krka pirmskontakta profilakses indikācijai”.
English: Paediatric population: The safety and efficacy of emtricitabine/tenofovir disoproxil in children under the age of 12 years have not been established (see section 5.2).
Latvian: Pediatriskā populācija: emtricitabīna/tenofovīra disoproksila drošums un efektivitāte, lietojot bērniem līdz 12 gadu vecumam,
English: Cmax: ↑ 79% (↑ 56 to ↑ 104) Cmin: ↑ 163% (↑ 137 to ↑ 197)
Latvian: AUC: ↑ 98% (↑ 77 līdz ↑ 123) Cmax: ↑ 79% (↑ 56 līdz ↑ 104) Cmin: ↑ 163% (↑ 137 līdz ↑ 197)
English: This adverse reaction may occur as a consequence of proximal renal tubulopathy.
Latvian: Šī blakusparādība var būt proksimālas nieru tubulopātijas sekas.
English: The recommended dose of Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV is:
Latvian: Ieteicamā Emtricitabine/Tenofovir disoproxil Krka deva HIV iegūšanas riska samazināšanai ir:
English: These may be signs of HIV infection: - tiredness - fever - joint or muscle aches - headache - vomiting or diarrhoea - rash - night sweats - enlarged lymph nodes in the neck or groin → Tell your doctor about any flu-like illness - either in the month before starting Emtricitabine/Tenofovir disoproxil Krka, or at any time while taking Emtricitabine/Tenofovir disoproxil Krka.
Latvian: Tālāk norādītas HIV infekcijas pazīmes: - nogurums; - drudzis; - locītavu vai muskuļu sāpes; - galvassāpes; - vemšana vai caureja; - izsitumi; - svīšana naktī; - palielināti limfmezgli uz kakla vai cirksnī.
English: Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.)
Latvian: C hepatīta vīrusa (HCV) pretvīrusu līdzekļi Ledipasvīrs/sofosbuvīrs (90 mg/400 mg q.d.) +
English: While taking Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV:
Latvian: Lietojot Emtricitabine/Tenofovir disoproxil Krka, lai samazinātu HIV iegūšanas risku:
English: neutropenia
Latvian: Izkliede
English: Adefovir dipivoxil and Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly (see section 4.4).
Latvian: Adefovīra dipivoksila un Emtricitabine/Tenofovir disoproxil Krka vienlaicīga lietošana nav ieteicama (skatīt 4.4. apakšpunktu).
English: Emtricitabine/Tenofovir disoproxil Krka is used to treat Human Immunodeficiency Virus 1 (HIV-1) infection in adults.
Latvian: - Emtricitabine/Tenofovir disoproxil Krka tiek lietots cilvēka imūndeficīta vīrusa 1. tipa
English: The safety of tenofovir disoproxil when used with ledipasvir/sofosbuvir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.
Latvian: Tenofovīra disoproksila drošums, lietojot līdz kopā ar sofosbuvīra/velpatasvīra un farmakokinētisko pastiprinātāju (piem., ritonavīru vai kobicistatu), nav noteikts.
English: Metabolism and nutrition disorders: Very common:
Latvian: alerģiska reakcija Vielmaiņas un uztures traucējumi Ļoti bieži:
English: In addition, the clinical response to treatment should be closely monitored in patients receiving Emtricitabine/Tenofovir disoproxil Krka at a prolonged dosing interval.
Latvian: Turklāt pacientiem, kuri saņem Emtricitabine/Tenofovir disoproxil Krka ar garākiem devu lietošanas starplaikiem, ir rūpīgi jākontrolē klīniskā atbildes reakcija uz ārstēšanu.
English: Other effects in children Children given emtricitabine very commonly experienced changes in skin colour including darkening of the skin in patches Children commonly experienced low red blood cell count (anaemia) - this may cause the child to be tired or breathless → If you notice any of these symptoms tell your doctor.
Latvian: Cita iedarbība uz bērniem - Bērniem, kuri lietoja emtricitabīnu, ļoti bieži novērotas ādas krāsas pārmaiņas, tai skaitā
English: Emtricitabine/Tenofovir disoproxil Krka.
Latvian: Ko Emtricitabine/Tenofovir disoproxil Krka satur
English: Cmin: ↑ 63% (↑ 45 to ↑ 84) Ritonavir:
Latvian: Cmin: ↑ 63% (↑ 45 līdz ↑ 84)
English: Cmin: ↑ 48% (↑ 34 to ↑ 63) Emtricitabine:
Latvian: Cmin: ↑ 48% (↑ 34 līdz ↑ 63)
English: Age (Yrs), Mean (SD)
Latvian: Vecums (gadi), vidējais (SN) Rase, N (%)
English: General disorders and administration site conditions: Very common:
Latvian: Vispārēji traucējumi un reakcijas ievadīšanas vietā Ļoti bieži:
English: Co-administration of Emtricitabine/Tenofovir disoproxil Krka and didanosine is not recommended (see section 4.4).
Latvian: Emtricitabine/Tenofovir disoproxil Krka un didanozīna vienlaicīga lietošana nav ieteicama (skatīt 4.4. apakšpunktu).
English: Cmax: ↓ 19% (↓ 40 to ↑ 10) GS-331007
Latvian: Cmax: ↓ 19% (↓ 40 līdz ↑ 10)
English: Detected sided 95% CI)
Latvian: Serokonversijas/N Sastopamība uz 100 persongadiem (95% TI)
English: AUC: ↑ 50% (↑ 42 to ↑ 59) Cmax: ↑ 64% (↑ 54 to ↑ 74) Cmin: ↑ 59% (↑ 49 to ↑ 70)
Latvian: Cmax: ↑ 64% (↑ 54 līdz ↑ 74) Cmin: ↑ 59% (↑ 49 līdz ↑ 70)
English: Placebo Emtricitabine/tenofovir disoproxil
Latvian: Emtricitabinum/Tenofovirum disoproxilum
English: Co-administration of tenofovir disoproxil and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosinerelated adverse reactions.
Latvian: 40 - 60%, kas var palielināt didanozīna izraisīto blakusparādību risku.
English: - That a multidisciplinary approach is recommended for the management of paediatric patients - That there is an increased risk of renal disease in HIV infected patients associated with tenofovir disoproxil-containing products such as Emtricitabine/Tenofovir disoproxil Krka - That Emtricitabine/Tenofovir disoproxil Krka is not recommended for use in paediatric patients with renal impairment - That use of Emtricitabine/Tenofovir disoproxil Krka should be avoided with concomitant or recent use of nephrotoxic medicinal products.
Latvian: - Ar HIV inficētiem pacientiem ir paaugstināts nieru slimības risks, kas saistīts ar tenofovīra disoproksila saturošām zālēm, piemēram, Emtricitabine/Tenofovir disoproxil Krka.
English: If you become pregnant, or plan to become pregnant, ask your doctor about the potential benefits and risks of therapy with Emtricitabine/Tenofovir disoproxil Krka to you and your child.
Latvian: Emtricitabine/Tenofovir disoproxil Krka terapijas iespējamo ieguvumu un risku Jums un Jūsu bērnam.
English: expected to decrease plasma concentrations of velpatasvir.
Latvian: Sagaidāms, ka sofosbuvīra/velpatasvīra un efavirenza vienlaicīga lietošana samazinās veltaspavīra koncentrāciju plazmā.
English: Gastrointestinal disorders: Very common:
Latvian: Kuņģa-zarnu trakta traucējumi Ļoti bieži:
English: Atazanavir/Ritonavir/Tenofovir disoproxil (300 mg q.d./100 mg q.d./245 mg q.d.)
Latvian: PRETINFEKCIJAS LĪDZEKĻI Pretretrovīrusu līdzekļi Proteāzes inhibitori Atazanavīrs/ritonavīrs/tenofovīra disoproksils (300 mg q.d./100 mg q.d./245 mg q.d.)
English: 3, nephrogenic diabetes insipidus
Latvian: hiperglikēmija hipertrigliceridēmija
English: anaemia
Latvian: astēnija
English: + Atazanavir/Ritonavir (300 mg q.d./100 mg q.d.)
Latvian: Atazanavīrs/ritonavīrs (300 mg q.d./100 mg q.d.) + Emtricitabīns/tenofovīra disoproksils
English: No dose adjustment of efavirenz is required.
Latvian: Nav nepieciešama efavirenza devas pielāgošana.
English: Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV infection - Reminder on the importance of strict adherence to the recommended dosing regimen - Provides information on how to take Emtricitabine/Tenofovir disoproxil Krka - Provides information on the possible side effects - Provides information on how to store Emtricitabine/Tenofovir disoproxil Krka.
Latvian: - Informatīvā brošūra par pirmskontakta profilaksi riskam pakļautam indivīdam “Svarīga informācija par Emtricitabine/Tenofovir disoproxil Krka, lai samazinātu inficēšanās ar cilvēka imūndeficīta vīrusu (HIV) risku”.
English: Cmax: ↓ 23% (↓ 30 to ↑ 16) Efavirenz:
Latvian: Cmax: ↓ 23% (↓ 30 līdz ↑ 16)
English: Oral administration.
Latvian: 7. tabula.
English: Emtricitabine/Tenofovir disoproxil Krka has not been studied in patients over 65 years of age.
Latvian: Krka nav pētīta pacientiem, kas vecāki par 65 gadiem.
English: Taking Emtricitabine/Tenofovir disoproxil Krka with other medicines that can damage your kidneys: it is especially important to tell your doctor if you are taking any of these medicines, including aminoglycosides (for bacterial infection) amphotericin B (for fungal infection) foscarnet (for viral infection) ganciclovir (for viral infection) pentamidine (for infections) vancomycin (for bacterial infection)
Latvian: Emtricitabine/Tenofovir disoproxil Krka lietošana kopā ar citām zālēm, kas var kaitēt Jūsu nierēm: ir īpaši svarīgi pastāstīt ārstam, ja Jūs lietojat jebkuras no šīm zālēm, tostarp:
English: Cmin: ↑ 45% (↑ 27 to ↑ 64) Emtricitabine:
Latvian: Cmin: ↑ 45% (↑ 27 līdz ↑ 64)
English: - Reminder of the key safety information regarding the use of Emtricitabine/Tenofovir disoproxil Krka for PrEP in adults and adolescents - Reminder of factors to help identify individuals at high risk of acquiring HIV 1 - Reminder on the risk of development of HIV 1 drug resistance in undiagnosed HIV 1
Latvian: - Galvenās drošuma informācijas saistībā ar Emtricitabine/Tenofovir disoproxil Krka lietošanu pirmskontakta profilaksei pieaugušajiem un pusaudžiem atgādinājums.
English: The following may be signs of lactic acidosis: deep rapid breathing drowsiness feeling sick (nausea), being sick (vomiting) stomach pain
Latvian: - dziļa, ātra elpošana; - miegainība; - slikta dūša, vemšana; - sāpes vēderā.
English: If you miss a dose
Latvian: Ja esat izlaidis devu
English: Increased plasma concentrations of tenofovir resulting from coadministration of tenofovir disoproxil, ledipasvir/sofosbuvir and atazanavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Latvian: Tenofovīra palielināta koncentrācija plazmā, ko izraisa tenofovīra disoproksils, sofosbuvīra/velpatasvīra un atazanavīra/ritonavīra vienlaicīga lietošana, var pastiprināt ar tenofovīra disoproksilu saistītas nevēlamas blakusparādības, tostarp nieru darbības traucējumus.
English: Common side effects (may affect up to 1 in 10 people) pain, stomach pain difficulty sleeping, abnormal dreams problems with digestion resulting in discomfort after meals, feeling bloated, flatulence rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches other allergic reactions, such as wheezing, swelling or feeling light-headed
Latvian: - sāpes, sāpes vēderā; - miega traucējumi, neparasti sapņi; - gremošanas traucējumi, kas rada nepatīkamu sajūtu pēc ēšanas, uzpūšanās sajūta, vēdera pūšanos;
English: Look out for any symptoms of infection or other symptoms such as: - muscle weakness - weakness beginning in the hands and feet and moving up towards the trunk of the body - palpitations, tremor or hyperactivity
Latvian: - muskuļu vājums; - vājums, kas sākas rokās un pēdās un pārvietojas uz rumpi;
English: Signs of osteonecrosis are: joint stiffness joint aches and pains (especially of the hip, knee and shoulder) difficulty with movement → If you notice any of these symptoms tell your doctor.
Latvian: - locītavu stīvums; - smeldze un sāpes locītavās (īpaši gūžas, ceļa un pleca locītavā); - apgrūtināta kustība.
English: Increased plasma concentrations of tenofovir resulting from co administration of tenofovir disoproxil, sofosbuvir/velpatasvir/voxilaprevir and darunavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Latvian: Tenofovīra palielināta koncentrācija plazmā, ko izraisa tenofovīra disoproksila, sofosbuvīra/velpatasvīra/voksilap revīra un darunavīra/ritonavīra vienlaicīga lietošana, var pastiprināt ar tenofovīra disoproksilu saistītas nevēlamas blakusparādības, tostarp nieru darbības traucējumus.